Business Wire
06 Dec 2025, 19:00 UTC · 45w ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Verdict
Headline takes no side. We score ACLX +1.00 — strongly bullish.
- Expected · ACLX
+1.00strongly bullish
−1 bearish0bullish +1More positive than 99% of ticker scores this week
- Actual





